Company Information

  

Address: 175 PORTLAND STREET
4TH FLOOR 
City: BOSTON 
State: MA 
Zip Code: 02114 
Telephone: 617-622-4003 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity. We are focused on developing novel therapeutics that treat the underlying biological mechanisms through the methionine aminopeptidase 2, or MetAP2, pathway. We have pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. Our lead product candidate is ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of metabolic diseases including type 2 diabetes and obesity. We are conducting a Phase 1 clinical trial of ZGN-1061 in the Netherlands, and have completed dosing patients in the single ascending dose, or SAD, portion and are currently dosing patients in the multiple ascending dose, or MAD, portion.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.88NAN/E
03/2017-1.95NAN/E
12/2016-2.12NAN/E
09/2016-2.60NAN/E
06/2016-2.79NAN/E
03/2016-2.90NAN/E
12/2015-2.78NAN/E
09/20150.75NA42.60

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.16Total Liab/Total Assets0.08
Net Inc/Total Assets-0.44Total Liab/Inv Cap0.08
Net Inc/Inv Cap-0.49Total Liab/Comm Equity0.03
Pretax Inc/Net SalesNAInterest Coverage Ratio-108.41
Net Inc/Net SalesNACurr Debt/Equity0.03
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.03
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio13.23
Inventory TurnoverNACurrent Ratio13.23
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.01 3.59 3.20 4.83
Operating Income -13.54 -13.27 -10.48 -14.83
Interest Exp 0.05 0.07 0.10 0.13
Pretax Income -13.35 -13.01 -10.44 -14.68
Other Income 0.24 0.33 0.13 0.29
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -13.35 -13.01 -10.44 -14.68

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 105.99 116.94 129.19 138.66
Receivables - Total 0.37 0.37 0.35 1.40
Inventories - Total NA NA NA NA
Total Current Assets 107.97 118.68 130.90 141.58
Net Property, Plant & Equipment 0.59 0.63 0.66 0.72
Total Assets 108.85 119.37 131.62 142.71
Liabilities        
Accounts Payable 7.16 5.76 6.31 8.22
Debt in Current Liabilities 2.06 2.84 3.59 3.12
Total Current Liabilities 9.22 8.60 9.89 11.34
Long-Term Debt NA NA 0.00 1.20
Total Liabilities 9.22 8.60 9.89 12.54
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.03 0.03 0.03 0.03
Retained Earnings -263.91 -250.56 -237.55 -227.11
Treasury Stock NA NA NA NA
Total Stockholders' Equity 99.63 110.77 121.73 130.17
Total Liabilities and Stockholders' Equity 108.85 119.37 131.62 142.71

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -10.18 -11.68 -8.67 -11.03
Net Cash Provided by Investing Activities 13.99 8.69 16.91 16.44
Net Cash Provided by Financing Activities -0.71 -0.73 -0.76 -0.58

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-13.88--
12/20130.00-14.03--
12/20140.00-36.48-0.30
12/20150.00-74.29-2.78
12/20160.00-57.88-2.12
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/179313,33548.52




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.